Tourette syndrome is a neurological condition that has no cure but can be managed with various strategies—some of which are ...

Relmada Therapeutics has acquired complete worldwide ownership rights to Sepranolone from Sweden-based Asarina Pharma.

For example, only 10% of people with Tourette have coprolalia, the involuntary swearing tic with which Dupree struggles, though it hasn't always been present in her behavior. When her symptoms ...

Relmada, which has turned to strategic options after scrapping two phase 3 trials in major depressive disorder (MDD), is ...

Phase 2a trials demonstrated Sepranolone's potential to significantly reduce Tourette symptoms and improve quality of life while maintaining a robust safety profile, making it a promising first ...

Relmada purchases Sepranolone, a Phase 2b ready asset, for the treatment of Tourette syndrome (TS) and other compulsion-related conditions from ...

Treatment of Tourette's syndrome is often unsatisfactory ... Thus, drug therapy is usually limited to those patients in whom symptoms cause impairment. However, not only severe tics are ...

Tourette syndrome is currently diagnosed about three times more frequently in males than in females. A new study finds that female individuals are less likely to be diagnosed with the syndrome, take ...

The therapy has shown potential in improving TS symptoms in an open-label Phase ... "Relmada acquires Tourette’s therapy rights from Asarina" was originally created and published by ...

Relmada purchases Sepranolone, a Phase 2b ready asset, for the treatment of Tourette syndrome (TS) and other compulsion-related conditions from Asarina Pharma AB Phase 2a results signaled ...